INITIAL RESULTS FROM RESOLVE, AN ONGOING PHASE 1B DOSE-ESCALATION STUDY OF EP-104GI (LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSION) FOR EOSINOPHILIC ESOPHAGITIS

被引：0
|
作者：
Helliwell, James
Malone, Amanda
Kowalski, Mark M.
Bredenoord, Arjan
Ko, Hin Hin
Nguyen, Nam Q.
Dobek, Christine
Peck, Vik
Dellon, Evan S.
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1279
引用
收藏
页码：S414 / S415
页数：2
相关论文
共 17 条
  • [1] Efficacy and Pharmacokinetic Results From Ongoing Dose Escalation in RESOLVE, a Phase 1b/2a Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis
    Malone, Amanda
    Helliwell, James
    Kowalski, Mark
    Bredenoord, Arjan
    Nguyen, Nam Quoc.
    Ko, Hin Hin
    Dobek, Christine
    Peck, Vik
    Byrne, Catherine
    Dye, Andrew
    Dellon, Evan S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S476 - S477
  • [2] PHARMACOKINETICS OF EP-104IAR LONG-ACTING FLUTICASONE PROPIONATE FOR INTRA ARTICULAR INJECTION IN 163 SUBJECTS FROM SPRINGBOARD, A PHASE 2 STUDY IN KNEE OSTEOARTHRITIS
    Helliwell, James A.
    Malone, Amanda
    Kowalski, Mark M.
    Dobek, Christine
    Peck, Vik
    Loss, Troy
    OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S296 - S296
  • [3] NKTR-255+CETUXIMAB IN PATIENTS WITH SOLID TUMORS: INTERIM SAFETY AND EFFICACY RESULTS FROM THE PHASE 1B DOSE-ESCALATION STUDY
    Altan, Mehmet
    Patnaik, Amita
    Barve, Minal
    Dunn, Lara
    Cobb, Patrick
    Rosenberg, Ari
    Sharma, Sunil
    Sukari, Ammar
    Patel, Manish
    Wang, Xiaoli
    Ma, Haijun
    Dixit, Neha
    Nieves, Wildaliz
    Fanton, Christie
    Currie, Sue
    Lee, Zachary
    Marcondes, Mario
    Zalevsky, Johnathan
    Tagliaferri, Mary
    Sacco, Assuntina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A1007 - A1007
  • [4] The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
    Martinez-Lopez, Joaquin
    Mustjoki, Satu
    Porkka, Kimmo
    Klisovic, Rebecca B.
    Wolf, Dominik
    Busque, Lambert
    Hernandez-Boluda, Juan Carlos
    Swanink, Rene
    Martin Regueira, Patricia
    Lipton, Jeffrey H.
    LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 2040 - 2043
  • [5] Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies
    Allan, John N.
    Patel, Krish
    Mato, Anthony R.
    Wierda, William G.
    Ibarz, Javier Pinilla
    Choi, Michael Y.
    O'Brien, Susan M.
    Sharman, Jeff P.
    Shadman, Mazyar
    Gladstone, Douglas E.
    Davids, Matthew S.
    Pagel, John M.
    Ward, Renee
    Acton, Gary
    Taverna, Pietro
    Fox, Judith A.
    Furman, Richard R.
    Brown, Jennifer R.
    BLOOD, 2019, 134
  • [6] Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies
    Ghobrial, Irene M.
    Savona, Michael R.
    Vij, Ravi
    Siegel, David S.
    Badros, Ashraf
    Kaufman, Jonathan L.
    Raje, Noopur
    Jakubowiak, Andrzej
    Obreja, Mihaela
    Berdeja, Jesus G.
    BLOOD, 2016, 128 (22)
  • [7] EFFICACY OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS: PER-PROTOCOL ANALYSES FROM SPRINGBOARD, A PHASE 2, RANDOMIZED, 24-WEEK STUDY OF EP-104IAR (LONG-ACTING INTRA-ARTICULAR INJECTION OF FLUTICASONE PROPIONATE)
    Helliwell, James A.
    Malone, Amanda
    Kowalski, Mark M.
    Rovsing, Helene
    Boll, Sidsel Lynggard
    Bihlet, Asger R.
    Miller, Claire Prener
    Mondragon, Alejandro Castillo
    Li, Yanqi
    Dobek, Christine
    Peck, Vik
    Wilmink, Mike
    Conaghan, Philip
    Simon, Lee S.
    OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S48 - S49
  • [8] Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenstrom Macroglobulinemia (WM)
    Siegel, David S.
    Kaufman, Jonathan L.
    Raje, Noopur S.
    Mikhael, Joseph R.
    Kapoor, Prashant
    Treon, Steven P.
    Castillo, Jorge J.
    Neuman, Linda L.
    Lee, Ju RueyJiuan
    Ghobrial, Irene
    BLOOD, 2014, 124 (21)
  • [9] Itolizumab, a Novel Anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-Escalation Study
    Putterman, Chaim
    Furie, Richard
    Radhakrishnan, Jai
    Mathur, Vandana S.
    Polu, Krishna R.
    Connelly, Stephen
    Rothman, Joel M.
    Ng, Cherie T.
    Chinn, Leslie
    Fung, Maple M.
    Thomas, Dolca
    Kalunian, Kenneth
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 506 - 506
  • [10] Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study
    Kalunian, Kenneth
    Furie, Richard
    Radhakrishnan, Jai
    Mathur, Vandana
    Polu, Krishna
    Connelly, Stephen
    Rothman, Joel
    Ng, Cherie
    Chinn, Leslie
    Fung, Maple
    Thomas, Dolca
    Putterman, Chaim
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3648 - 3650
12